Effective August 2, 2022, mdxhealth has acquired the Oncotype DX GPS (Genomic Prostate Score) test from Exact Sciences. To help ensure a smooth transition for patients, continue to place orders for this test through the existing Exact Sciences portal until further notice. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the Oncotype DX GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the following press release. Questions? Email: gps@mdxhealth.com

PIPELINE & DATA

Our pipeline team is responsible for advancing our future tests and developing life-changing cancer diagnostics to help patients throughout the course of their diagnosis and treatment.

 

Breast Radiation Score

COLOGUARD® 2.0

COLORECTAL CANCER BLOOD

LBgard® Blood Tubes

Minimal Residual Disease

Multi-Cancer Early Detection

Exact Academy

Publications & Abstracts